Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2008-04-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-07-0393PMID 18413797
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase.

  2007cited by this paper
• Brain tumors

  2007cited by this paper
• Use of an Orthotopic Xenograft Model for Assessing the Effect of Epidermal Growth Factor Receptor Amplification on Glioblastoma Radiation Response

  2006cited by this paper
• A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.

  2006cited by this paper
• A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling

  2006influential reference
• Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?

  2006cited by this paper
• A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

  2006cited by this paper
• Methylation of the ATM promoter in glioma cells alters ionizing radiation sensitivity.

  2006cited by this paper
• Clonogenic cell survival assay.

  2005cited by this paper
• Inhibition of phosphatidylinositol-3-kinase causes increased sensitivity to radiation through a PKB-dependent mechanism.

  2005cited by this paper
• Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.

  2005cited by this paper
• PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas

  2005cited by this paper
• The Akt/PKB pathway: molecular target for cancer drug discovery

  2005cited by this paper
• The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas.

  2004cited by this paper
• Biochemical characterization of the ataxia-telangiectasia mutated (ATM) protein from human cells.

  2004cited by this paper
• Spontaneous activation and signaling by overexpressed epidermal growth factor receptors in glioblastoma cells

  2003cited by this paper
• Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002.

  2003cited by this paper
• Activation of the Phosphatidylinositol‐3′‐Kinase/Protein Kinase B‐Dependent Antiapoptotic Pathway Plays an Important Role in the Development of Radioresistance of Human Glioma Cells

  2002cited by this paper
• An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross-linking agents.

  2002cited by this paper
• TSC1–TSC2: a complex tale of PKB-mediated S6K regulation

  2002cited by this paper
• Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

  2002cited by this paper
• Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival.

  2002cited by this paper
• Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy.

  2002cited by this paper
• Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.

  2001cited by this paper
• PDK2: A Complex Tail in One Akt

  2001cited by this paper
• Specificity and mechanism of action of some commonly used protein kinase inhibitors.

  2000cited by this paper
• Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications.

  2000cited by this paper
• The conditional probability of survival of patients with primary malignant brain tumors

  1999cited by this paper
• Signaling by distinct classes of phosphoinositide 3-kinases.

  1999cited by this paper
• Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin.

  1998cited by this paper
• PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.

  1997cited by this paper
• Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay.

  1997cited by this paper
• Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene.

  1996cited by this paper
• Studies on the mechanism of phosphatidylinositol 3-kinase inhibition by wortmannin and related analogs.

  1996cited by this paper
• The p53 gene and its role in human brain tumors

  1995cited by this paper
• Computer programs for the analysis of cellular survival data.

  1987cited by this paper
• Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves.

  1985cited by this paper
• Adjuvant therapy for brain tumor.

  1980cited by this paper

• Access to Chromenopyrrole via Tandem [3 + 2] Cycloaddition and Intramolecular C-O Coupling.

  2024cites this paper
• Combined inhibition of class 1-PI3K-alpha and delta isoforms causes senolysis by inducing p21WAF1/CIP1 proteasomal degradation in senescent cells

  2024cites this paper
• Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta

  2024cites this paper
• Preliminary In Vitro and In Vivo Insights of In Silico Candidate Repurposed Drugs for Alzheimer’s Disease

  2023cites this paper
• Cu-Catalyzed decarboxylative annulation of N-substituted glycines with 3-formylchromones: synthesis of functionalized chromeno[2,3-b]pyrrol-4(1H)-ones.

  2022cites this paper
• Multicomponent Cascade Reaction of 3-Cyanochromones: Highly Site-Selective Synthesis of 2-(1H-Imidazol-1-yl)-4H-chromen-4-one Derivatives.

  2022cites this paper
• Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth

  2019cites this paper
• Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells

  2018cites this paper
• Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme.

  2017cites this paper
• Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia

  2017cites this paper
• Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy

  2017cites this paper
• Lysophosphatidic Acid Signalling Enhances Glioma Stem Cell Properties

  2017cites this paper
• Lipidomics of Stem Cells

  2017cites this paper
• Tumor Microenvironment, Hypoxia, and Stem Cell-Related Radiation Resistance

  2016cites this paper
• Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

  2016cites this paper
• Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3Kβ and PI3Kδ for the treatment of PTEN-deficient cancers.

  2015cites this paper
• Improving chemoradiation efficacy by PI3-K/AKT inhibition.

  2014cites this paper
• Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness

  2014cites this paper
• Radiotherapy and the tumor microenvironment: mutual influence and clinical implications.

  2014cites this paper
• Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.

  2014cites this paper
• Tumor Microenvironment and Cellular Stress

  2014influential citation
• Potent phosphatidylinositol 3-kinase inhibitors and their biology.

  2014cites this paper
• Inhibitors of the Phosphatidylinositol 3-Kinase Pathway

  2014cites this paper
• Overcoming resistance to rapalogs in gliomas by combinatory therapies.

  2013cites this paper
• mTOR pathway in colorectal cancer: an update

  2013cites this paper
• Glioblastoma cancer stem cells: role of the microenvironment and therapeutic targeting.

  2013cites this paper
• Stem Cell‐Based Combination Therapies for Cancer

  2013cites this paper
• Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway

  2013cites this paper
• The Protective Effect of Berberis aristata against Mitochondrial Dysfunction Induced due to Co-administration of Mitomycin C andCisplatin

  2012cites this paper
• SF1126, a Pan-PI3K Inhibitor has Potent Pre-Clinical Activity in Aggressive B-Cell Non-Hodgkin Lymphomas by Inducing Cell Cycle Arrest and Apoptosis

  2012cites this paper
• Chloroquine or Chloroquine-PI3K/Akt Pathway Inhibitor Combinations Strongly Promote γ-Irradiation-Induced Cell Death in Primary Stem-Like Glioma Cells

  2012cites this paper
• PI3K–AKT–mTOR inhibitors for the systemic treatment of endometrial cancer

  2012cites this paper
• The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.

  2011cites this paper
• A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.

  2011cites this paper
• Class III phosphoinositide 3-kinase in melanoma

  2011cites this paper
• The Role Of Phosphoinositide 3-Kinase Gamma In The Host Immune Response Against Cutaneous Leishmaniasis Caused by Leishmania mexicana

  2011cites this paper
• Hypoxia-Inducible Factor in Thyroid Carcinoma

  2011cites this paper
• Advances in malignant glioma drug discovery

  2011cites this paper
• Potential role of PI3K inhibitors in the treatment of breast cancer.

  2010cites this paper
• Characterisation of SHIP-1 as a regulator of T lymphocyte function

  2010cites this paper
• Caffeine Confers Radiosensitization of PTEN-Deficient Malignant Glioma Cells by Enhancing Ionizing Radiation–Induced G1 Arrest and Negatively Regulating Akt Phosphorylation

  2010cites this paper
• PI 3 K / p 110 is a novel therapeutic target in multiple myeloma

  2010cites this paper
• Akt signaling pathway: a target for radiosensitizing human malignant glioma.

  2010cites this paper
• PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

  2010cites this paper
• Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.

  2010cites this paper
• Theaflavins target Fas/caspase-8 and Akt/pBad pathways to induce apoptosis in p53-mutated human breast cancer cells.

  2010cites this paper
• The dual PI3K/mTOR inhibitor PI‐103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib‐treated melanoma cells

  2010cites this paper
• PI3Kα Inhibitors That Inhibit Metastasis

  2010cites this paper
• PI3K/p110 (cid:1) is a novel therapeutic target in multiple myeloma

  2010cites this paper
• The PI3K pathway as drug target in human cancer.

  2010cites this paper
• Preclinical Study of PI3K and BRAF Inhibitors in Malignant Melanoma

  2010cites this paper
• The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair

  2009influential citation
• Cell signalling and radiation survival: The impact of protein phosphatases

  2009cites this paper
• Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors

  2009cites this paper
• A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.

  2009cites this paper
• Novel experimental targeted therapy of neuroblastoma

  2009cites this paper
• Elimination of Cancer Stem Cells

  2009cites this paper
• Chapter 17 Emerging Therapies Based on Inhibitors of Phosphatidyl-Inositol-3-Kinases

  2009cites this paper
• Novel inhibitors of the PI3K family

  2009cites this paper
• Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

  2009cites this paper
• Modulating the tumor microenvironment to increase radiation responsiveness

  2009cites this paper
• Rôle de la voie de signalisation Interleukine-6 dans la radiorésistance des glioblastomes humains

  2009cites this paper
• Radiosensitising agents for the radiotherapy of cancer: novel molecularly targeted approaches

  2009cites this paper
• Tumor vascular changes mediated by inhibition of oncogenic signaling.

  2009cites this paper
• PI3K Signaling in Glioma—Animal Models and Therapeutic Challenges

  2009cites this paper
• Progress in the design and development of phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of chronic diseases.

  2009cites this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cites this paper
• Drug discovery approaches targeting the PI3K/Akt pathway in cancer

  2008cites this paper
• A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.

  2008cites this paper
• A novel dual PI 3 K · / mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells

  year unknowncites this paper